BN.com Gift Guide

Elucidating microRNA-mediated regulation of estrogen signaling and response in human breast cancer cells.

More About This Textbook

Overview

Basal-like breast cancers are more invasive, of a higher grade, and confer poorer clinical prognosis than ERalpha-positive, Luminal-A cancers. Unfortunately, mechanisms by which this ERalpha-negative tumor subtype arises remain obscure. MicroRNAs are small noncoding RNAs that diminish the stability and/or translation of mRNAs. To determine whether microRNAs are involved in generating an ERalpha-negative Basal-like tumor subtype, we first investigated if miR-206, previously shown to be elevated in ERalpha-negative breast tumors, could regulate ERalpha expression. We demonstrated that two miR-206 binding sites located within the 3'-UTR of human ERalpha mRNA were functionally active in ERalpha-positive, MCF-7 breast cancer cells. We also demonstrated that miR-206 coordinately targets mRNAs encoding the co-activator proteins SRC-1 and SRC-3, and the transcription factor GATA-3, in turn abrogating global ERalpha/estradiol signaling in MCF-7 cells. Moreover, overexpression of miR-206 in MCF-7 cells resulted in decreased cell proliferation, enhanced apoptosis, diminished expression of numerous estrogen-responsive genes, and a loss of a Luminal-A phenotype. We then investigated whether the signaling pathways known to be disrupted in breast cancer were potential regulators of miR-206. While miR-206 levels were inhibited by estradiol and ERalpha agonists in MCF-7 cells, EGFR siRNA treatments and MEK inhibitors indicated EGFR/MAPK signaling promotes miR-206 levels in ERalpha-negative, EGFR-positive MDA-MB-231 cells. Furthermore, blocking EGF-induced enhancement of miR-206 abrogated the known EGF inhibitory effects on estrogenic responses in MCF-7 cells. While these findings elucidate the involvement of microRNAs in the induction of a Luminal-A to Basal-like phenotypic switch in breast cancer cells, little is known regarding the dysregulation of Argonaute-2 (the catalytic engine of microRNA effector complexes) that also occurs within breast cancer. We demonstrated that high levels of Argonaute-2 in ERalpha-negative vs. ERalpha-positive breast cancer cell lines, was due to hyperactive EGFR/MAPK signaling. Also, the stable overexpression of Argonaute-2 in MCF-7 cells resulted in enhanced proliferation, reduced cell-cell adhesion, and increased migratory ability, indicating that Argonaute-2 may induce tumorigenic progression in ERalpha-positive breast cancer cells. Overall, miR-206 and Argonaute-2 are highly dysregulated in breast cancer due to gain of ancillary oncogenic signaling pathways, can actively modulate breast tumorigenic processes, and could become novel biomarkers for this disease.
Read More Show Less

Product Details

  • BN ID: 2940032298618
  • Publisher: ProQuest LLC
  • Sold by: Barnes & Noble
  • Format: eTextbook
  • Pages: 222

Customer Reviews

Be the first to write a review
( 0 )
Rating Distribution

5 Star

(0)

4 Star

(0)

3 Star

(0)

2 Star

(0)

1 Star

(0)

Your Rating:

Your Name: Create a Pen Name or

Barnes & Noble.com Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & Noble.com that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & Noble.com does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at BN.com or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation

Reminder:

  • - By submitting a review, you grant to Barnes & Noble.com and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Noble.com Terms of Use.
  • - Barnes & Noble.com reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & Noble.com also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on BN.com. It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

 
Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously

    If you find inappropriate content, please report it to Barnes & Noble
    Why is this product inappropriate?
    Comments (optional)